Immunotherapy cost for kidney cancer — what the bill is actually made of

There is no single figure, which is why nobody quotes one honestly. Immunotherapy is billed per cycle, and cycles repeat, so the number that matters is the running cost over months rather than a one-off price. The indicative range CION publishes for combination immunotherapy is ₹1,50,000 to ₹3,50,000 or more per cycle. Where a targeted tablet is given alongside it, that adds an indicative ₹25,000 to ₹1,20,000 a month. Where your own case sits inside those ranges depends on which combination is chosen, your dosing, how many cycles are planned before the first assessment scan, and what your scheme or insurance covers. Ask for a written estimate once your reports have been reviewed.

Because nobody knows at the start how many cycles you will have. Treatment is given on a repeating schedule with a gap of a few weeks between doses, and how long it continues depends on whether it is working, how well you tolerate it, and the plan agreed at the outset. A single grand total would either be guesswork or an over-estimate built to be safe. The honest way to budget is to take the per-cycle figure, multiply it by the number of cycles planned before the first assessment scan, and treat that as your first block of spending. Then ask what the review point is, and what the plan becomes if treatment is changed.

Eligible kidney cancer treatment may be largely covered under Aarogyasri and PMJAY at empanelled centres, and our team checks your eligibility before anything is booked rather than after. For private cover, CION works with all major TPAs for cashless hospitalisation, and an EMI facility is available for patients paying themselves. How much is actually covered depends on your policy wording, your sum insured, any waiting period, and whether the treatment is delivered as day care or as an admission. Day-care cover is the detail most often missed on an older policy. Bring your policy document and your ration card or scheme details to the first consultation so this is settled early.

Per cycle, immune-based treatment given as a drip usually carries the larger sticker price, and a targeted tablet taken at home shows a lower monthly figure. The comparison is not that simple, though, because the two are not interchangeable and in advanced kidney cancer they are often given together rather than one instead of the other. The useful question is not which is cheaper but which fits your risk group, your pathology and your other medical conditions, and then what that costs to run for the number of months planned. A cheaper drug that is not the right drug is not a saving. Ask for the options set side by side, with the cost of each, in writing.

Ask for that split explicitly, because it varies between centres. A per-cycle figure usually covers the drug, the day-care chair and the nursing time for the infusion. What often sits outside it is the blood work before each cycle, the thyroid, kidney and liver monitoring, the assessment scans, and treatment for any side effect that needs it. At CION the infusions, the monitoring bloodwork and the management of immune-related side effects are led in-house by our medical oncology team. Kidney surgery, ablation and PET-CT are coordinated with specialist partner centres, where they may also be billed separately, so those belong in your budget as their own lines.

Bring or send what you already have, which means the scans, the pathology report and recent blood results, and ask for the estimate in writing. A useful estimate names the treatment being proposed, the cost per cycle, the number of cycles planned before the first assessment scan, what is included, what is billed separately, and what the alternative is if the plan changes. At CION every case goes to a tumour board before that estimate is given, so the plan you are pricing is the plan the team actually recommends along NCCN lines. The first consultation is free and there is no commitment to start treatment.